A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS: Patients received vorinostat orally once daily on days 1–14...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schelman, William R., Traynor, Anne M., Holen, Kyle D., Kolesar, Jill M., Attia, Steven, Hoang, Tien, Eickhoff, Jens, Jiang, Zhisheng, Alberti, Dona, Marnocha, Rebecca, Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Espinoza-Delgado, Igor, Wright, John J., Wilding, George, Bailey, Howard H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901262/
https://ncbi.nlm.nih.gov/pubmed/24114121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0029-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados